Isomorphic Labs closes $2.1bn funding round
Isomorphic Labs, the London based artificial intelligence specialist spun out of Google DeepMind, has secured $2.1bn billion dollars in a Series B funding round to accelerate its work on drug discovery. This capital injection marks a significant milestone for the drug design sector and highlights growing investor confidence in the application of generative AI within the life sciences and healthcare…
Novo Nordisk appoints new president and CEO as it focuses on U.S. weight-loss drug market
Novo Nordisk appointed Maziar Mike Doustdar as its new CEO and president on August 7, 2025, signalling a strategic shift to address challenges in the U.S. weight-loss drug market and competition from Eli Lilly. Doustdar, the first non-Danish leader in the company’s history, emphasised refocusing on the firm’s core strengths in obesity and diabetes while trimming its pipeline to prioritize speed and execution. His…